Annotation Detail
Information
- Associated Genes
- FLT3
- Associated Variants
-
FLT3 ITD
FLT3 ITD - Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- 13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients showed clearance or near clearance of bone marrow myeloblasts after 27 (range 21-84) days with evidence of differentiation of leukemia cells. Sorafenib response was lost in most patients after 72 (range 54-287) days.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1040
- Gene URL
- https://civic.genome.wustl.edu/links/genes/24
- Variant URL
- https://civic.genome.wustl.edu/links/variants/55
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Sorafenib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22368270
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Sorafenib | Sensitivity | true |